Klein Dov 4
4 · Fortress Biotech, Inc. · Filed Apr 29, 2022
Insider Transaction Report
Form 4
Klein Dov
Director
Transactions
- Other
Common Stock, par value $0.001
2021-09-30+480→ 655,785 total - Award
Common Stock, par value $0.001
2022-01-01+100,000→ 751,015 total - Other
Common Stock, par value $0.001
2021-08-05+305→ 655,305 total - Other
Common Stock, par value $0.001
2021-11-16+230→ 656,015 total - Sale
Common Stock, par value $0.001
2021-12-28$2.45/sh−5,000$12,250→ 651,015 total
Footnotes (5)
- [F1]The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock.
- [F2]The total holdings include 480,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units.
- [F3]The shares were issued upon the consummation of Journey Medical Corporation ("Journey's") initial public offering as a partial dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey's 8% Cumulative Convertible Class A Preferred Stock.
- [F4]One-third of the shares will vest on each of January 1, 2023, 2024 and 2025, subject to continued service. The reporting person elected to defer 80,000 of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer.
- [F5]The total holdings include 560,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units.